Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Corcept Therapeutics (CORT) Long-Term Deferred Tax (2017 - 2025)

Historic Long-Term Deferred Tax for Corcept Therapeutics (CORT) over the last 9 years, with Q3 2025 value amounting to $153.0 million.

  • Corcept Therapeutics' Long-Term Deferred Tax rose 2066.26% to $153.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $153.0 million, marking a year-over-year increase of 2066.26%. This contributed to the annual value of $130.9 million for FY2024, which is 4448.87% up from last year.
  • Per Corcept Therapeutics' latest filing, its Long-Term Deferred Tax stood at $153.0 million for Q3 2025, which was up 2066.26% from $162.2 million recorded in Q2 2025.
  • In the past 5 years, Corcept Therapeutics' Long-Term Deferred Tax ranged from a high of $162.2 million in Q2 2025 and a low of $27.5 million during Q4 2021
  • In the last 5 years, Corcept Therapeutics' Long-Term Deferred Tax had a median value of $78.2 million in 2023 and averaged $83.4 million.
  • As far as peak fluctuations go, Corcept Therapeutics' Long-Term Deferred Tax crashed by 1312.53% in 2021, and later surged by 12387.54% in 2022.
  • Over the past 5 years, Corcept Therapeutics' Long-Term Deferred Tax (Quarter) stood at $27.5 million in 2021, then skyrocketed by 123.88% to $61.5 million in 2022, then skyrocketed by 47.41% to $90.6 million in 2023, then surged by 44.49% to $130.9 million in 2024, then rose by 16.87% to $153.0 million in 2025.
  • Its last three reported values are $153.0 million in Q3 2025, $162.2 million for Q2 2025, and $144.4 million during Q1 2025.